Literature DB >> 15900598

Chromosome 1q loss of heterozygosity frequently occurs in sporadic insulinomas and is associated with tumor malignancy.

Ying-Mai Yang1, Tong-Hua Liu, Yuan-Jia Chen, Wei-Jun Jiang, Jia-Ming Qian, Xin Lu, Jie Gao, Sha-Fei Wu, Xin-Ting Sang, Jie Chen.   

Abstract

The pathogenesis of sporadic insulinomas is not clear, and there are no reliable genetic determinants that are useful to distinguish malignant and benign forms of this tumor. It was reported that 1q LOH might contribute to pathogenesis in gastrinomas and was correlated with tumor progression. However, little data are available on 1q LOH in sporadic insulinomas. In our study, we determine whether 1q LOH occurs in sporadic insulinomas and is associated with tumor malignancy by performing 1q allelotyping with 17 markers in 40 tumors and pair normal DNA. Thirty-five (88%) insulinomas had 1q LOH. Of the 35 insulinomas with 1q LOH, 14 (40%) had 1q21.3-23.2 LOH over a 7.5 cM region (SRO-1), whereas LOH in 21 tumors (60%) occurred at 1q31.3 over an 11.4 cM area (SRO-2). Of 24 tumors without MEN1 LOH, 20 had either SRO-1 or SRO-2 LOH (83%), whereas in 16 tumors with MEN1 LOH, 9 were shown to have LOH at either SRO-1 or SRO-2 (56%) (p = 0.065). This result suggests that LOH at 2 SRO might be MEN1 gene independent and may contribute to the pathogenesis in a subset of insulinomas without MEN1 gene LOH. The presence of 1q21.3-23.2 LOH is significantly associated with malignancy of insulinomas (p = 0.014). The high frequency of LOH at 1q 21.3-23.2 and 1q31.3 suggests these 2 areas may harbor putative tumor suppressor genes that may play an important role in the tumorigenesis of a subset of insulinomas. LOH at 1q21.3-23.2, which was associated with tumor malignancy, could be one of the genetic markers for identifying malignancy in sporadic insulinomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15900598     DOI: 10.1002/ijc.21175

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Downregulation of CRNN gene and genomic instability at 1q21.3 in oral squamous cell carcinoma.

Authors:  Iman Salahshourifar; Vui King Vincent-Chong; Hong-Yun Chang; Hooi Leng Ser; Anand Ramanathan; Thomas George Kallarakkal; Zainal Ariff Abdul Rahman; Siti Mazlipah Ismail; Narayanan Prepageran; Wan Mahadzir Wan Mustafa; Mannil Thomas Abraham; Keng Kiong Tay; Rosnah Binti Zain
Journal:  Clin Oral Investig       Date:  2015-04-08       Impact factor: 3.573

2.  PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors.

Authors:  Rieko Ohki; Kozue Saito; Yu Chen; Tatsuya Kawase; Nobuyoshi Hiraoka; Raira Saigawa; Maiko Minegishi; Yukie Aita; Goichi Yanai; Hiroko Shimizu; Shinichi Yachida; Naoaki Sakata; Ryuichiro Doi; Tomoo Kosuge; Kazuaki Shimada; Benjamin Tycko; Toshihiko Tsukada; Yae Kanai; Shoichiro Sumi; Hideo Namiki; Yoichi Taya; Tatsuhiro Shibata; Hitoshi Nakagama
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-27       Impact factor: 11.205

3.  Refined mapping of loss of heterozygosity on 1q31.1-32.1 in sporadic colorectal carcinoma.

Authors:  Chong-Zhi Zhou; Guo-Qiang Qiu; Jun-Wei Fan; Xiao-Liang Wang; Hua-Mei Tang; Li Huang; Yu-Hao Sun; Zhi-Hai Peng
Journal:  World J Gastroenterol       Date:  2008-03-14       Impact factor: 5.742

Review 4.  A vicious partnership between AKT and PHLDA3 to facilitate neuroendocrine tumors.

Authors:  Masahiro Takikawa; Rieko Ohki
Journal:  Cancer Sci       Date:  2017-05-22       Impact factor: 6.716

Review 5.  p53-PHLDA3-Akt Network: The Key Regulators of Neuroendocrine Tumorigenesis.

Authors:  Yu Chen; Rieko Ohki
Journal:  Int J Mol Sci       Date:  2020-06-08       Impact factor: 5.923

6.  Characterization of tumor suppressive function of cornulin in esophageal squamous cell carcinoma.

Authors:  Kai Chen; Yan Li; Yongdong Dai; Jiangchao Li; Yanru Qin; Yinghui Zhu; Tingting Zeng; Xiaojiao Ban; Li Fu; Xin-Yuan Guan
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

7.  Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas.

Authors:  Xin-Wei Qiao; Ling Qiu; Yuan-Jia Chen; Chang-Ting Meng; Zhao Sun; Chun-Mei Bai; Da-Chun Zhao; Tai-Ping Zhang; Yu-Pei Zhao; Yu-Li Song; Yu-Hong Wang; Jie Chen; Chong-Mei Lu
Journal:  BMC Endocr Disord       Date:  2014-08-07       Impact factor: 2.763

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.